GO:0000159 protein phosphatase type 2A complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000159 describes the protein phosphatase type 2A (PP2A) complex, a serine/threonine phosphatase holoenzyme built from catalytic, scaffolding and regulatory subunits.
• PP2A is polycation-stimulated and acts as a central regulator of numerous signaling pathways, making it one of the most important phosphatases in eukaryotic cells.
• The PP2A core enzyme consists of a catalytic subunit and a scaffolding subunit, while the holoenzyme adds a variable regulatory subunit that determines substrate specificity.
• PP2A function intersects with autophagy, lipid metabolism and liver disease, and its dysregulation is linked to cancer and neurodegeneration.
• Studying PP2A requires integrated approaches including CRISPR knockout, point mutation, knock-in, overexpression, proteomics and imaging.
• EDITGENE provides CRISPR cell model services to dissect PP2A subunit function in disease-relevant contexts.
Description
The protein phosphatase type 2A complex (GO:0000159) is a cellular component defined as a protein complex with polycation-stimulated serine/threonine phosphatase activity that is directly stimulated by protamine, polylysine or histone H1. It constitutes a subclass of several enzymes activated by different histones and polylysine, and it consists of catalytic, scaffolding and regulatory subunits; the catalytic and scaffolding subunits form the core enzyme, while the holoenzyme also includes the regulatory subunit. Because PP2A controls the phosphorylation status of a vast array of signaling proteins, it is a central node in cellular regulation and a frequent focus of biomedical research. Researchers study GO:0000159 to understand how reversible phosphorylation governs cell growth, metabolism, autophagy and stress responses. The complex is not a single static entity but a family of holoenzymes whose composition and localization determine which substrates are dephosphorylated. This combinatorial assembly explains why PP2A can influence seemingly unrelated processes such as gut microbiota-inflammatory crosstalk, hepatic lipid handling and neuronal survival. For publication-ready work, precise definition of the PP2A complex and its subunits is essential, because experimental conclusions about signaling, autophagy or disease depend on knowing which holoenzyme is being studied. This article summarizes the authoritative GO definition, the structure and regulation of the complex, its disease relevance, and the CRISPR-based methods used to interrogate it.
protein phosphatase type 2A complex At A Glance
| GO ID | GO:0000159 |
|---|---|
| GO term | protein phosphatase type 2A complex |
| Ontology | cellular_component |
| Synonym | PP2A complex; PP2A-pi; PP2a-protector; protein phosphatase 2 complex |
| Major function | Polycation-stimulated protein serine/threonine phosphatase activity that dephosphorylates signaling proteins |
| Subunit composition | Catalytic, scaffolding and regulatory subunits; core enzyme plus regulatory subunit forms holoenzyme |
| Stimulation | Directly stimulated by protamine, polylysine or histone H1 |
| Pathway context | Regulator of numerous signaling pathways, autophagy, lipid metabolism and disease processes |
What Is GO:0000159?
In simple terms, GO:0000159 describes the PP2A holoenzyme: a molecular machine that removes phosphate groups from serine and threonine residues on other proteins. According to the QuickGO definition, it is a protein complex with protein serine/threonine phosphatase activity that is polycation-stimulated (PCS), being directly stimulated by protamine, polylysine or histone H1; it constitutes a subclass of several enzymes activated by different histones and polylysine, and consists of catalytic, scaffolding and regulatory subunits. The catalytic and scaffolding subunits form the core enzyme, and the holoenzyme also includes the regulatory subunit. This definition distinguishes PP2A from other phosphatases by its subunit architecture and its characteristic stimulation by polycations.
Why Is protein phosphatase type 2A complex Important in Cell Biology?
The PP2A complex is important because it is one of the principal serine/threonine phosphatases that counterbalance kinase-driven signaling, and its dysfunction is associated with major human diseases including cancer, metabolic liver disease and neurodegeneration. Because PP2A activity is polycation-stimulated and dependent on regulatory subunits, it integrates diverse cellular inputs and controls processes such as autophagy, inflammatory responses and lipid droplet dynamics. Understanding GO:0000159 therefore provides a mechanistic foundation for therapeutic strategies that target phosphorylation signaling.
• PP2A is a central regulator of numerous signaling pathways through reversible protein phosphorylation.
• The complex is directly stimulated by protamine, polylysine or histone H1, defining its polycation-stimulated activity.
• PP2A holoenzymes contain variable regulatory subunits that dictate substrate specificity and subcellular localization.
• PP2A intersects with autophagy, gut microbiota and inflammatory responses in inflammatory bowel disease.
• Therapeutic regulation of autophagy in hepatic metabolism involves PP2A-sensitive signaling.
• PP2A is implicated in the interplay between autophagy, lipid droplets and liver disease.
• Autophagy regulation by PP2A is relevant to physiological endometrium and cancer.
• Targeting autophagy with small molecules in Parkinson's disease engages phosphatase-dependent pathways.
• Defective autophagy in neurodevelopmental, neuromuscular and neurodegenerative disorders involves phosphatase signaling.
• CRISPR models of PP2A subunits enable causal testing of signaling hypotheses.
What Happens During protein phosphatase type 2A complex?
Holoenzyme assembly and substrate recruitment
In simple terms: The PP2A machine is built from three parts, and the third part decides which proteins it acts on.
The PP2A core enzyme is formed by a catalytic subunit and a scaffolding subunit, and the holoenzyme additionally includes a regulatory subunit that determines substrate specificity. This combinatorial assembly allows a limited number of catalytic subunits to generate many distinct holoenzymes with different targets and locations. The regulatory subunit is therefore a key determinant of which signaling pathways are dephosphorylated.
Polycation-stimulated dephosphorylation
In simple terms: Certain positively charged molecules can switch the phosphatase on.
PP2A activity is polycation-stimulated (PCS), being directly stimulated by protamine, polylysine or histone H1. This distinguishes PP2A from other phosphatases and links its activity to the local charge environment and chromatin-associated proteins. The stimulation profile is part of the authoritative definition of GO:0000159.
Dephosphorylation of serine and threonine residues
In simple terms: The enzyme removes phosphate tags from target proteins.
The complex has protein serine/threonine phosphatase activity, meaning it removes phosphate groups from serine and threonine residues of substrate proteins. By reversing kinase-mediated phosphorylation, PP2A modulates the activity, stability and interactions of numerous signaling proteins. This catalytic function underlies its role as a complex regulator of numerous signaling pathways.
Integration with autophagy and metabolic signaling
In simple terms: PP2A helps decide when cells recycle their own components and how they handle fats.
PP2A-dependent signaling intersects with autophagy, gut microbiota and inflammatory responses in inflammatory bowel disease. Therapeutic regulation of autophagy in hepatic metabolism also involves phosphatase-sensitive pathways. Furthermore, the interplay between autophagy, lipid droplets and liver disease highlights PP2A as a node connecting metabolic and degradative processes.
Roles in cell survival and disease pathways
In simple terms: When PP2A goes wrong, cells can survive abnormally or die prematurely.
Autophagy regulation by PP2A is relevant to the physiological endometrium and cancer, where altered phosphatase activity can affect cell survival. Targeting autophagy with small-molecule compounds in Parkinson's disease engages phosphatase-dependent mechanisms. Defective autophagy in neurodevelopmental, neuromuscular and neurodegenerative disorders further implicates PP2A in neuronal maintenance.
Key Genes Involved in GO:0000159 protein phosphatase type 2A complex
The following genes and proteins represent the core subunits and key regulators of the protein phosphatase type 2A complex (GO:0000159) as described in the authoritative literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPP2CA | Catalytic subunit alpha of PP2A | Core enzyme activity and substrate dephosphorylation |
| PPP2CB | Catalytic subunit beta of PP2A | Catalytic subunit isoform in PP2A holoenzymes |
| PPP2R1A | Scaffolding subunit A alpha | Core enzyme assembly and holoenzyme formation |
| PPP2R1B | Scaffolding subunit A beta | Scaffolding subunit isoform in PP2A complexes |
| PPP2R2A | Regulatory subunit B alpha | Substrate specificity and localization of PP2A |
| PPP2R2B | Regulatory subunit B beta | Regulatory control of PP2A holoenzymes |
| PPP2R2C | Regulatory subunit B gamma | Tissue-specific regulation of PP2A |
| PPP2R2D | Regulatory subunit B delta | Regulatory subunit diversity in PP2A |
| PPP2R3A | Regulatory subunit B'' alpha | Alternative regulatory subunit family |
| PPP2R3B | Regulatory subunit B'' beta | Regulatory subunit function in PP2A |
| PPP2R3C | Regulatory subunit B'' gamma | Holoenzyme specificity and signaling |
| PPP2R5A | Regulatory subunit B56 alpha | B56 family regulation of PP2A substrates |
| PPP2R5B | Regulatory subunit B56 beta | B56 family regulatory function |
| PPP2R5C | Regulatory subunit B56 gamma | B56 family control of PP2A activity |
| PPP2R5D | Regulatory subunit B56 delta | B56 family regulatory subunit |
| PPP2R5E | Regulatory subunit B56 epsilon | B56 family regulatory subunit |
| PPME1 | PP2A methylesterase | Regulation of PP2A catalytic subunit methylation |
How Is protein phosphatase type 2A complex Regulated?
PP2A complex activity is regulated at multiple levels, including holoenzyme composition through the choice of regulatory subunit, which determines substrate specificity and localization. The catalytic and scaffolding subunits form the core enzyme, and the holoenzyme also includes the regulatory subunit, so changes in regulatory subunit expression or availability directly alter PP2A function. PP2A is polycation-stimulated, being directly stimulated by protamine, polylysine or histone H1, which provides an additional layer of charge-dependent regulation. Because PP2A is a complex regulator of numerous signaling pathways, its activity is also integrated with autophagy and metabolic signaling networks.
protein phosphatase type 2A complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPP2CA | Cancer and signaling dysregulation | CRISPR knockout in cancer cell lines |
| PPP2R1A | Hepatic metabolism and liver disease | Knock-in of patient variants in hepatocytes |
| PPP2R2A | Inflammatory bowel disease and autophagy | Knockout in intestinal epithelial cells |
| PPP2R5C | Endometrial cancer and autophagy | Overexpression in endometrial cell lines |
| PPP2R5D | Neurodevelopmental disorders | Point mutation knock-in in neuronal models |
PP2A in inflammatory bowel disease and gut microbiota
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in inflammatory bowel disease highlight phosphatase-dependent signaling as a contributor to intestinal inflammation. PP2A complexes modulate autophagy and inflammatory pathways that are dysregulated in IBD, making them relevant to disease mechanisms and therapeutic targeting.
PP2A in hepatic metabolism and liver disease
Therapeutic regulation of autophagy in hepatic metabolism involves PP2A-sensitive signaling, linking the phosphatase to liver metabolic control. The ménage à trois of autophagy, lipid droplets and liver disease further positions PP2A at the intersection of lipid storage and degradation pathways. These findings suggest that PP2A dysfunction may contribute to steatosis and related liver pathologies.
PP2A in cancer and endometrium
Autophagy in the physiological endometrium and cancer is regulated in part by phosphatase-dependent mechanisms, and PP2A activity can influence cell survival decisions in these tissues. Because PP2A is a complex regulator of numerous signaling pathways, its dysregulation may promote tumorigenesis or alter therapeutic responses.
PP2A in neurodegenerative and neurodevelopmental disorders
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease engages phosphatase-dependent pathways. The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorders due to defective autophagy further implicates PP2A in neuronal maintenance and disease. Together, these studies support a role for PP2A complexes in neurological health.
From protein phosphatase type 2A complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PP2A catalytic subunit alter autophagy flux? | CRISPR knockout of PPP2CA |
| Does a specific regulatory subunit mutation change substrate specificity? | Point mutation knock-in of PPP2R2A |
| Can a disease-associated variant be corrected? | Knock-in of wild-type allele |
| Where is the PP2A holoenzyme localized? | Tagged knock-in of PPP2R1A |
| Does overexpression of a regulatory subunit drive transformation? | Overexpression of PPP2R5C |
| Which pathways depend on PP2A in liver cells? | Knockout plus transcriptomics in hepatocytes |
How to Study the protein phosphatase type 2A complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of PP2A subunit function | Testing causal roles in signaling |
| Point mutation knock-in | Effect of specific amino acid changes | Modeling disease variants |
| Knock-in tagging | Localization and interactions | Imaging PP2A holoenzymes |
| Overexpression | Gain-of-function effects | Regulatory subunit studies |
| Proteomics | Subunit composition and interactors | Defining PP2A holoenzymes |
| Autophagy flux assay | Degradative pathway activity | IBD and liver disease models |
| Lipid droplet imaging | Lipid storage dynamics | Liver disease research |
| Transcriptomics | Pathway-level gene expression changes | PP2A-dependent networks |
CRISPR-based genetic perturbation
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of PP2A subunit function in disease-relevant cells. These approaches can dissect the contributions of catalytic, scaffolding and regulatory subunits to holoenzyme activity.
Proteomics and interactomics
Proteomic analysis of PP2A complexes can identify subunit composition and interacting partners, helping to define which holoenzymes are present in a given cell state. Such data complement functional assays of phosphatase activity.
Autophagy and metabolic assays
Because PP2A intersects with autophagy and lipid metabolism, assays measuring autophagic flux and lipid droplet dynamics are informative readouts. These methods link PP2A activity to cellular phenotypes relevant to IBD, liver disease and cancer.
Imaging and localization studies
Fluorescence imaging of tagged PP2A subunits reveals subcellular localization and holoenzyme dynamics. Localization data are essential for understanding how PP2A reaches its substrates in different signaling contexts.
How CRISPR Can Be Used to Study GO:0000159 protein phosphatase type 2A complex
Knockout
CRISPR knockout of PP2A catalytic, scaffolding or regulatory subunit genes eliminates specific holoenzyme functions, enabling researchers to test which signaling pathways depend on GO:0000159. Knockout models are particularly useful for distinguishing essential from redundant subunits.
Point Mutation
Point mutation knock-in can model disease-associated amino acid substitutions in PP2A subunits, revealing how subtle changes alter phosphatase activity or substrate specificity. Such models are valuable for mechanistic studies of signaling dysregulation.
Knock-in
Knock-in of tagged or wild-type PP2A subunits allows precise tracking of holoenzyme localization and correction of disease variants. These models support imaging and interaction studies in physiologically relevant cells.
Overexpression
Overexpression of PP2A regulatory subunits can reveal gain-of-function effects on autophagy, metabolism and cell survival. Such models complement loss-of-function approaches to define the full dynamic range of PP2A activity.
How EDITGENE Supports protein phosphatase type 2A complex Research
Researchers studying protein phosphatase type 2A complex-related genes often need to determine whether a candidate gene is causally involved in a signaling, metabolic or disease phenotype. This requires precise genetic models that isolate the contribution of individual PP2A subunits within the holoenzyme. EDITGENE provides the CRISPR tools and bioinformatics support needed to build such models and interpret the resulting data in the context of GO:0000159.
Contact EDITGENE today to design your custom CRISPR model for protein phosphatase type 2A complex research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PPP2R5B Knockout HEK293 Cell Line | EDJ-KQ270 | Human | 5526 | Details Get a Quote |
| NKD1 Knockout HEK293 Cell Line | EDJ-KQ317 | Human | 85407 | Details Get a Quote |
| PPP2R1B Knockout HEK293 Cell Line | EDJ-KQ395 | Human | 5519 | Details Get a Quote |
| PPP2R2A Knockout HEK293 Cell Line | EDJ-KQ851 | Human | 5520 | Details Get a Quote |
| PPP2R2B Knockout HEK293 Cell Line | EDJ-KQ852 | Human | 5521 | Details Get a Quote |
| PPP2R3A Knockout HEK293 Cell Line | EDJ-KQ854 | Human | 5523 | Details Get a Quote |
| PPP2R5A Knockout HEK293 Cell Line | EDJ-KQ855 | Human | 5525 | Details Get a Quote |
| PPP2R5C Knockout HEK293 Cell Line | EDJ-KQ856 | Human | 5527 | Details Get a Quote |
| PPP2R5D Knockout HEK293 Cell Line | EDJ-KQ857 | Human | 5528 | Details Get a Quote |
| PPP2R5E Knockout HEK293 Cell Line | EDJ-KQ859 | Human | 5529 | Details Get a Quote |
| PPP2CB Knockout HEK293 Cell Line | EDJ-KQ1370 | Human | 5516 | Details Get a Quote |
| PPP2R2C Knockout HEK293 Cell Line | EDJ-KQ1372 | Human | 5522 | Details Get a Quote |
| PPP2R2D Knockout HEK293 Cell Line | EDJ-KQ1373 | Human | 55844 | Details Get a Quote |
| PTPA Knockout HEK293 Cell Line | EDJ-KQ3709 | Human | 5524 | Details Get a Quote |
| IER5 Knockout HEK293 Cell Line | EDJ-KQ11011 | Human | 51278 | Details Get a Quote |
Displaying Records 1 To 15 Of 73 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About protein phosphatase type 2A complex
What is GO:0000159?
GO:0000159 is the Gene Ontology cellular component term for the protein phosphatase type 2A complex, a polycation-stimulated serine/threonine phosphatase holoenzyme with catalytic, scaffolding and regulatory subunits.
What is the protein phosphatase type 2A complex?
It is a protein complex that removes phosphate groups from serine and threonine residues and is directly stimulated by protamine, polylysine or histone H1.
What genes are involved in the protein phosphatase type 2A complex?
Key genes include PPP2CA, PPP2CB, PPP2R1A, PPP2R1B and multiple regulatory subunit genes such as PPP2R2A, PPP2R5A and PPP2R5C.
What are the subunits of PP2A?
PP2A consists of catalytic, scaffolding and regulatory subunits; the catalytic and scaffolding subunits form the core enzyme, and the holoenzyme also includes the regulatory subunit.
How is PP2A activity stimulated?
PP2A is polycation-stimulated, being directly stimulated by protamine, polylysine or histone H1.
Why is PP2A important in disease?
PP2A regulates numerous signaling pathways and is linked to inflammatory bowel disease, liver disease, cancer and neurodegenerative disorders.
How do researchers study PP2A complexes?
They use CRISPR knockout, point mutation, knock-in, overexpression, proteomics, autophagy assays and imaging to dissect PP2A function.
What is the role of PP2A in autophagy?
PP2A-dependent signaling intersects with autophagy in inflammatory bowel disease, hepatic metabolism and cancer.
Can CRISPR be used to model PP2A mutations?
Yes, CRISPR point mutation and knock-in models can reproduce disease-associated variants in PP2A subunits.
What services does EDITGENE provide for PP2A research?
EDITGENE provides knockout, point mutation, knock-in, overexpression, CRISPR library screening and bioinformatics services for PP2A-related genes.
Conclusion
The protein phosphatase type 2A complex (GO:0000159) is a polycation-stimulated serine/threonine phosphatase holoenzyme with catalytic, scaffolding and regulatory subunits that serves as a central regulator of numerous signaling pathways. Its involvement in autophagy, metabolism, inflammation and neurological disease makes it a high-value target for mechanistic and translational research. By combining precise CRISPR models with proteomic and imaging readouts, researchers can define how individual PP2A subunits contribute to health and disease. EDITGENE supports this work with end-to-end cell model and bioinformatics services tailored to GO:0000159.
References
- 1. Larabi A et al.. 2020. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.. Autophagy 16(1):38-51 PMID: 31286804
- 2. Byrnes K et al.. 2022. Therapeutic regulation of autophagy in hepatic metabolism.. Acta Pharm Sin B 12(1):33-49 PMID: 35127371
- 3. Filali-Mouncef Y et al.. 2022. The ménage à trois of autophagy, lipid droplets and liver disease.. Autophagy 18(1):50-72 PMID: 33794741
- 4. Zolnierowicz S. 2000. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways.. Biochem Pharmacol 60(8):1225-35 PMID: 11007961
- 5. Devis-Jauregui L et al.. 2021. Autophagy in the physiological endometrium and cancer.. Autophagy 17(5):1077-1095 PMID: 32401642
- 7. Zhang K et al.. 2021. Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.. Acta Pharm Sin B 11(10):3015-3034 PMID: 34729301
- 8. Deneubourg C et al.. 2022. The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorders due to defective autophagy.. Autophagy 18(3):496-517 PMID: 34130600
